Member Info for ISAInvestor

Bye then! Keep an eye on how the trials pan out.

Given the lack of liquidity here for the last couple of years, the situation hasn't changed much apart from the fact that Charles won't have to foot the £500k a year bill it costs to have ANA listed here. Yes, we'll lose ISA status on any investments made that way. That's a shame but SIPPs are not affected. I've voted in favour of delisting and the next thing will be to see results of trials start to come through.

If the company goes private - and I'm voting for it - the trials can still be successful and Ananda goes on to market medication, or is bought by someone who wants to do that, then the returns should be worth it. Only if the company is declared bankrupt or is sold at these levels could it be be described as disastrous.

Ridiculous comment. Melissa has bought millions of shares this year.

Nice to see Melissa taking advantage of the bargain prices. When the US listing comes the prices of the last years will seem insanely low.

I think it's something to do with the wide spread between sell and buy.

The trades are recorded by AQSE but LSE just makes wild guesses sometimes - LSE is not an accurate trading tool.

Try *Ananda Pharma Investor Group*

Good price to buy in at - welcome!

There's also a Telegram group you can join...it's more active than here.

Word is getting out, no doubt. Bit of a relief for those who have been nibbling away for years!

'This is why we are taking the classic drug development route to cannabinoid medicines. A while ago this seemed like the longer, riskier route to widely prescribed cannabis medicines. I no longer believe that to be the case at all.'

https://www.linkedin.com/search/results/all/?fetchDeterministicClustersOnly=true&heroEntityKey=urn%3Ali%3Afsd_profile%3AACoAACSgxZEBRT7QBYyymhv_zwJZXyDeuvWaz7U&keywords=melissa%20sturgess&origin=RICH_QUERY_TYPEAHEAD_HISTORY&position=0&searchId=a7736fef-4987-4007-8c04-e9807dff3368&sid=Clw&spellCorrectionEnabled=true

Yes, it's positive for long-term investors. Sitting tight for an exciting ride into 2025 here...

It's so obvious that with NHS-funded trials in the pipeline that ANA is undervalued. Doubling or trebling current value would be conservative IMHO.

Not putting a foot wrong. Patience will pay.

Not putting a foot wrong. Patience will pay.

*ATH* obviously... doh.

Very strong presentation. I think being back at our ATM within six months is perfectly achievable.

...and yet still such a low price for anyone wanting to invest in a highly-promising medical start-up. Very interesting times ahead!

If you're expecting the price to double from here then I'd say that's quite positive. Looking forward to getting back to those levels ASAP!

Better to spend you time elsewhere, rather than trolling here then surely... why be in a chat for a company you have no interest in investing in?

Yes, I recall Melissa quickly realising it was a waste of her time. As you say, some of the those on here (and in the Telegram group) are known outside the chats and are certainly not on the board!